Polyagglutination: Rare but Real

Myth: Polyagglutination is so rare it doesn't matter in clinical practice.

Often Misunderstood or Overlooked

Most transfusion professionals may go their entire careers without knowingly encountering a case of polyagglutination – and that’s precisely why it’s often misunderstood or overlooked. Because it is rare, the myth persists that it’s irrelevant. But when polyagglutination does occur, it can create diagnostic confusion, delay transfusions, or even mask more dangerous pathologies. Polyagglutination refers to a patient’s red blood cells (RBCs) agglutinating with virtually all normal human sera due to exposure of cryptantigens on the RBC surface. In healthy individuals, these cryptantigens remain hidden. In certain pathological states – especially some bacterial infections – microbial enzymes can cleave portions of the red cell membrane (like removing sialic acid), uncovering antigenic determinants such as the T, Tk, Th, or Tx antigens that are usually “silent.” Once exposed, these cryptantigens cause the patient’s RBCs to agglutinate when tested against random adult serum (since most people have natural IgM antibodies against them).
 

Unexplained Agglutination can Lead the Team Down a Rabbit Hole

Clinically, a patient with polyagglutination might show panagglutination in compatibility testing or antibody identification panels – everything reacts, which can be mistaken for a warm autoantibody or other polyreactive scenario. In newborn testing, polyagglutination can cause spurious positive results (since cord serum or certain reagents might not react the same way as adult serum). In immunocompromised or septic patients, unexplained agglutination can lead the team down a rabbit hole investigating autoimmune hemolysis, wasting precious time. Worse, polyagglutination patterns might mask true alloantibodies, making it difficult to find compatible blood until the issue is recognized.

Rare Hereditary Forms

There are also very rare hereditary forms of polyagglutination, such as the Cad phenotype or HEMPAS (hereditary erythroblastic multinuclearity with a positive acidified serum test). These are usually discovered incidentally when abnormal serologic reactions occur including ABO blood typing. Individuals often don’t have overt hemolysis from it. But in transfusion testing, their RBCs will agglutinate broadly unless specific techniques are used. Fortunately, there are ways to identify polyagglutination. Lectin panels (e.g. using Arachis hypogaea for T antigen exposure) can confirm certain types. Testing the patient’s RBCs with cord serum (which lacks many of the natural antibodies present in adult serum) can reveal that reactions go away with cord serum, pointing to polyagglutination. Enzyme treatments and other specialized tests can help pinpoint the type of polyagglutination.

Important to Avoid Misdiagnosis

No specific treatment is required for polyagglutination itself – it’s a lab phenomenon. However, its presence is a red flag that may signal an underlying issue: often an infection (like Clostridium perfringens sepsis in classic T-activation, or other bacterial causes), or in rare cases a hematologic disorder. Thus, recognizing polyagglutination is important to avoid misdiagnosis and ensure the patient’s blood bank workup is handled correctly (for instance, using autologous serum or cord serum for crossmatches, so that compatible blood can be found).

Rare Does not Equal Never

Yes, polyagglutination is rare – but when it occurs, it matters. Knowing about it can prevent unnecessary panic or mismanagement. It reminds us that not all strange agglutination is an autoantibody or an allergy; sometimes the RBCs are just presenting the wrong handshake to everyone else’s plasma. As with many things in transfusion medicine, rare does not equal never – and being prepared for the outliers keeps patients safe.